FDA Revokes EUA For Solo Use Of Lilly’s COVID-19 Antibody Bamlanivimab

By Beth Wang / April 16, 2021 at 6:42 PM
FDA on Friday (April 16) revoked emergency use authorization for Eli Lilly’s COVID-19 monoclonal antibody therapy bamlanivimab, when used as a single therapy, coming nearly one month after HHS stopped distribution of the drug due to increased spread of COVID-19 variants that are resistant to bamlanivimab when it’s administered by itself. Bamlanivimab is still authorized for use with Lilly’s etesevimab for treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. As of mid-March, approximately 20% of viruses sequenced in...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.